526 related articles for article (PubMed ID: 26621451)
1. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.
Chen Y; Bai G; Ning Y; Cai S; Zhang T; Song P; Zhou J; Duan W; Ding J; Xie H; Zhang H
Eur J Med Chem; 2020 Mar; 190():112092. PubMed ID: 32014679
[TBL] [Abstract][Full Text] [Related]
3. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88
Scott JS; Degorce SL; Anjum R; Culshaw J; Davies RDM; Davies NL; Dillman KS; Dowling JE; Drew L; Ferguson AD; Groombridge SD; Halsall CT; Hudson JA; Lamont S; Lindsay NA; Marden SK; Mayo MF; Pease JE; Perkins DR; Pink JH; Robb GR; Rosen A; Shen M; McWhirter C; Wu D
J Med Chem; 2017 Dec; 60(24):10071-10091. PubMed ID: 29172502
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and pharmacological evaluation of 2,3-dihydrobenzofuran IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma.
Chen Y; Ning Y; Chen Z; Xue Y; Wu Q; Duan W; Ding J; Zhou J; Xie H; Zhang H
Eur J Med Chem; 2023 Aug; 256():115453. PubMed ID: 37163947
[TBL] [Abstract][Full Text] [Related]
6. Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation.
Zhang J; Fu L; Shen B; Liu Y; Wang W; Cai X; Kong L; Yan Y; Meng R; Zhang Z; Chen YP; Liu Q; Wan ZK; Zhou T; Wang X; Gavine P; Del Rosario A; Ahn K; Philippar U; Attar R; Yang J; Xu Y; Edwards JP; Dai X
Cell Chem Biol; 2020 Dec; 27(12):1500-1509.e13. PubMed ID: 32888499
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
[TBL] [Abstract][Full Text] [Related]
8. Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825.
Wang X; Tan Y; Huang Z; Huang N; Gao M; Zhou F; Hu J; Feng W
Oncol Rep; 2019 Nov; 42(5):1755-1766. PubMed ID: 31432184
[TBL] [Abstract][Full Text] [Related]
9. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
[TBL] [Abstract][Full Text] [Related]
10. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
Goldstein RL; Yang SN; Taldone T; Chang B; Gerecitano J; Elenitoba-Johnson K; Shaknovich R; Tam W; Leonard JP; Chiosis G; Cerchietti L; Melnick A
J Clin Invest; 2015 Nov; 125(12):4559-71. PubMed ID: 26529251
[TBL] [Abstract][Full Text] [Related]
12. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.
Lyu MA; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Rosenblum MG
Biochem Pharmacol; 2010 Nov; 80(9):1335-42. PubMed ID: 20654581
[TBL] [Abstract][Full Text] [Related]
13. IRAK4 inhibition to shut down TLR signaling in autoimmunity and MyD88-dependent lymphomas.
Küppers R
J Exp Med; 2015 Dec; 212(13):2184. PubMed ID: 26666751
[No Abstract] [Full Text] [Related]
14. Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.
Seltzer J; Moorad R; Schifano JM; Landis JT; Dittmer DP
J Virol; 2020 May; 94(10):. PubMed ID: 32161170
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT.
Paul J; Soujon M; Wengner AM; Zitzmann-Kolbe S; Sturz A; Haike K; Keng Magdalene KH; Tan SH; Lange M; Tan SY; Mumberg D; Lim ST; Ziegelbauer K; Liu N
Cancer Cell; 2017 Jan; 31(1):64-78. PubMed ID: 28073005
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88
Degorce SL; Anjum R; Bloecher A; Carbajo RJ; Dillman KS; Drew L; Halsall CT; Lenz EM; Lindsay NA; Mayo MF; Pink JH; Robb GR; Rosen A; Scott JS; Xue Y
J Med Chem; 2019 Nov; 62(21):9918-9930. PubMed ID: 31622099
[TBL] [Abstract][Full Text] [Related]
17. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Yang G; Buhrlage SJ; Tan L; Liu X; Chen J; Xu L; Tsakmaklis N; Chen JG; Patterson CJ; Brown JR; Castillo JJ; Zhang W; Zhang X; Liu S; Cohen P; Hunter ZR; Gray N; Treon SP
Blood; 2016 Jun; 127(25):3237-52. PubMed ID: 27143257
[TBL] [Abstract][Full Text] [Related]
18. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.
Ma J; Xing W; Coffey G; Dresser K; Lu K; Guo A; Raca G; Pandey A; Conley P; Yu H; Wang YL
Oncotarget; 2015 Dec; 6(41):43881-96. PubMed ID: 26575169
[TBL] [Abstract][Full Text] [Related]
19. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.
Xu D; Kim Y; Postelnek J; Vu MD; Hu DQ; Liao C; Bradshaw M; Hsu J; Zhang J; Pashine A; Srinivasan D; Woods J; Levin A; O'Mahony A; Owens TD; Lou Y; Hill RJ; Narula S; DeMartino J; Fine JS
J Pharmacol Exp Ther; 2012 Apr; 341(1):90-103. PubMed ID: 22228807
[TBL] [Abstract][Full Text] [Related]
20. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M
Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]